Citable company snapshot
Thermo Fisher Scientific's latest SEC-sourced 2026-06-27 period shows $11.99B in revenue and $1.74B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 27, 2026 | $11.99B | $11.01B | +9.0% |
| Gross Profit | Dec 31, 2019 | $3.04B | $2.76B | +9.8% |
| Operating Income | Jun 27, 2026 | $2.09B | $1.86B | +12.0% |
| Net Income | Jun 27, 2026 | $1.74B | $1.65B | +5.1% |
| Operating Cash Flow (computed) | Jun 27, 2026 | $2.13B | $1.19B | +78.3% |
| Free Cash Flow (computed) | Jun 27, 2026 | $1.68B | $816.00M | +105.3% |
Source: SEC EDGAR financial statements; period Jun 27, 2026; filed Jul 31, 2026; accession 0000097745-26-000144.
TMO company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.